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Follicular lymphoma is the second most frequent non-Hodgkin lymphoma accounting for about
10-20% of all lymphomas in western countries. The median age at diagnosis is 60 years old. The
clinical presentation is usually characterized by asymptomatic peripheral adenopathy in cervical,
axillary, inguinal and femoral regions. Treatment options for patients with naïve or recurrent
follicular lymphoma are still controversial, ranging from a "watch and wait" policy to hematopoietic
stem cell transplantation. More recently, the availability of rituximab has substantially changed
follicular lymphoma therapeutic approaches to such an extent that R-Chemo is now the standard
induction first-line treatment. This review provides a general overview of the state of the art in the
management of follicular lymphoma and also, a brief description regarding the current prognostic
tools available for treatment decisions.
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Introduction
Follicular lymphoma (FL) is the second most frequent non-Hodgkin lymphoma
accounting for about 10-20% of all lymphomas in western countries. The median age at
diagnosis is 60 years old and there is a slight predominance in women.(1)
Clinical presentation is characterized by asymptomatic peripheral adenopathy in
cervical, axillary, inguinal and femoral regions. Also, waxing and waning lymph node
enlargement for years is common. Bone marrow involvement is present in more than 50%
of patients. The disease is usually characterized by an indolent clinical course response
to initial therapy with frequent relapses and shorter duration responses to salvage
therapy.(2)
Treatment options for patients with naïve or recurrent FL are still controversial,
ranging from a "watch and wait" policy to hematopoietic stem cell transplantation. More
recently, the availability of rituximab has substantially changed FL therapeutic
approaches, to such an extent that R-chemo is now the standard induction first-line
treatment. The introduction of rituximab is considered to be at least partly responsible
for the improved median overall survival (OS).(3-5)
This review will provide a brief description regarding the current prognostic tools
available for treatment decisions and a general overview of the state of the art in the
management of limited and advanced FL.
Prognostic factors
So far, only a few biological parameters have been validated for defining prognosis
in patients with FL that are currently managed according to their clinical and laboratory
features. The most important parameters for defining treatment when a new FL is
diagnosed are the patient's conditions and the extent of disease.
A patient's status is usually established by assessment of age and performance
status, which have been widely confirmed as independent prognostic factors.(6,7) Disease
extension is usually acknowledged as one the most important prognostic factors for
patients with FL. It can be assessed either directly by means of the Ann Arbor staging
system or indirectly by means of surrogates such as tumor burden, bulky disease and
bone marrow involvement. In addition to Ann Arbor Staging, and mainly for patients
with advanced disease, single clinical parameters contributing to the quality of advanced
stage have been correlated with prognosis; these include the number of nodal or
extranodal sites of disease, the presence and the extent of bone marrow involvement,
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the involvement of certain specific locations, or the presence
of a large tumor diameter. Clinical and laboratory parameters
have also been investigated as indirect or surrogate measures
of lymphoma extent and are considered to be independent
prognostic variables in different prognostic models. These
parameters include the presence of B-symptoms, low
hemoglobin level (< 10 g/dL), elevated erythrocyte
sedimentation rate (ESR), lactic dehydrogenase (LDH) and
β2-microglobulin (B2M) values (above normal).(8)
Prognostic scores
There are currently several prognostic indexes that
have been developed to predict survival of FL patients.
The most relevant among these were developed by the
Italian Lymphoma Intergroup (ILI)(6) and the International
Follicular Lymphoma Prognostic Factor Project (IFLPFP).(7)
The ILI score is based on the independent prognostic roles
of age, gender, B symptoms, number of extranodal sites, ESR
and LDH. These 6 variables defined a prognostic model with
3 risk groups associated with different 5- and 10-year survival
rates. The advantages of the ILI model over the International
Prognostic Index (IPI) model are the remarkably higher
discriminating power between groups and the ability to
identify a higher number of under 60-year-old patients with a
poor prognosis. The IFLPFP score was developed more
recently as the result of a large international cooperative effort.
The score was defined on a training series of 1795 patients
and was based on five risk factors: age, Ann Arbor stage,
hemoglobin level, number of nodal site areas and serum LDH
level. Based on the final model, patients with 0 or 1 vs. 2 risk
factors were characterized by 5-year OS of 91% and 78%,
respectively; while those with 3 or more risk factors, who
represented 27% of all cases, had 5- and 10-year OS rates of
53% and 36%, respectively.(7) When IFLPFP scores were also
tested between under and over 60-year-old patients, with the
exception of age, the previously identified risk factors
remained independent prognostic factors.
In 2003 the IFLPFP started a study which was aimed
at verifying whether a prospective collection of data would
succeed in developing a more accurate prognostic index.
The final results of the study, which accrued 1093 new FL
cases between 2003 and 2005 registered at 69 European
and American Institutions, have been recently disclosed.
Progression free survival (PFS) was chosen as the main
efficacy endpoint in order to provide a clinically useful
index and to allow for an acceptable factor/event ratio
necessary to perform a reliable multivariate analysis. Of
note, rituximab was used in 60% of patients, either as a
single agent or in combination chemotherapy.(9) This new
scoring system is based on the identification of 5 parameters,
including age, bone marrow involvement, hemoglobin level,
B2M value and longest diameter of largest lymph node
(Table 1). Based on the number of risk factors, patients
were stratified into 3 risk groups: score 0 (20%): low risk;
score 1-2 (53%): intermediate risk; and score 3-5 (27%):
high risk. The 5-year PFS rates were 79%, 51%, and 20%,
respectively for each risk category (p-value < 0.00001) The
model was also predictive of PFS in patients treated either
with or without rituximab (p-value < 0.0001). The 3-year
survival rates were 99%, 96%, and 84%, respectively, for
each risk category.
Treatment strategies in limited stage
follicular lymphoma
Approximately 10-20% of FL patients present in limited
stages (I-II) and half of them could enjoy durable remission
after treatment with involved field radiation therapy (RT). In
a population large study of the Surveillance, Epidemiology
and End Results (SEER database) of 6568 patients with stage
I and II diagnosed from 1973-2004, patients who received RT
enjoyed higher 5- (90% versus 81%), 10- (79% versus 66%)
and 20-year (63% versus 51%) disease-specific survival rates
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and also of 5- (81% versus 71%), 10- (61% versus 48%) and
20-year (35% versus 23%) overall survival rates, when
compared with other therapeutic approaches.(10)
Moreover, in selected stage I and II patients, deferred
therapy is an acceptable approach. In a retrospective analysis
from Stanford University, more than half of patients remained
untreated at a median of 6 or more years, and survival was
comparable to that observed in patients undergoing
immediate treatment.(11)
Treatment strategies in advanced follicular
lymphoma
The vast majority of patients have advanced disease
at diagnosis and the current approach is to offer immediate
treatment only for patients presenting with active or
symptomatic disease (Table 2). This approach is supported
by randomized clinical trials that compared observation
(watch and wait) versus immediate treatment which show
that immediate treatment does not yield longer survival.(12-14)
At present, the open question is whether these conclusions
are still valid in the era of rituximab and only randomized
clinical trials will be able to answer this.
Monotherapy with rituximab
The availability of a single agent, rituximab, represents
a tempting choice for patients especially for those who have
been selected for treatment deferral. The use of rituximab as
a monotherapy in low tumor burden FL patients has recently
been addressed in a randomized clinical trial conducted by
Ardeshna et al.(15) The preliminary results of the study
showed that immediate use of rituximab significantly
prolonged time to initiation of new therapy compared to
watchful waiting. The investigators reported that rituximab
was well tolerated and had no impact on quality of life;
however no differences in terms of OS has been described
as yet thus it still remains to be proven if immediate treatment
with rituximab in patients with low tumor burden FL will
really be beneficial.
Front-line immunochemotherapy
The benefit of adding rituximab to combination
chemotherapy has been established in some randomized
trials. All of them have shown improvements in response
rates, time to progression or overall survival (Table 3).(16-19)
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Currently, the open question is what is the best
chemotherapy regimen to add to rituximab? The CHOP
regimen (cyclophosphamide, doxorubicin, vincristine,
prednisone) is by far the most used.(20) However CVP
(cyclophosphamide, vincristine, prednisone) and
fludarabine-containing regimens are also adopted. The
FOLL05 trial by the Fondazione Italiana Linfomi (FIL) was
recently concluded with the enrollment of 534 patients. This
study compared R-CVP, R-CHOP and R-FM in stage II-/IV
FL patients. In the preliminary analysis presented at the XI
International Conference on Malignant Lymphoma, Lugano
in 2011, it was shown that R-CVP was associated to an inferior
3-year time to treatment failure (TTF) (47%) compared to
R-FM (60%) and R-CHOP (57%). In addition, R-CHOP had
an anti-lymphoma activity similar to R-FM but a better
toxicity profile and may now be considered the standard
regimen in the treatment of patients with advanced FL.(21)
Other combinations of chemotherapeutic agents with
rituximab have been reported. Bendamustine plus rituximab
(B+R) was compared to R-CHOP in patients with advanced
FL, mantle cell, and other indolent lymphoma subtypes. B+R
yielded a higher complete remission rate (40% versus 30%,
p-value = 0.03) and also a longer PFS (55 months versus 35
months, p-value < 0.01) compared with R-CHOP. In addition
to the improved outcome, patients treated with B+R had
significantly lower toxicity both in terms of hematological
and extra-hematological events.(22) If these results are
confirmed it is likely that R+B will become, in the near future,
an important treatment option for patients with newly
diagnosed FL, in particularly for the elderly.
Maintenance
The use of maintenance strategies after initial treatment
in FL has been considered over a long time. The use of
interferon was evaluated and showed benefits in terms of
duration of remission and survival; however the safety
profile of the drug and the low manageability of treatment
has led most physicians to abandon this treatment option.(23)
The availability of rituximab as a single effective and low-
toxicity agent has suggested the possibility of using it not
only to improve efficacy of chemotherapy but also to delay
progression after initial treatment.
So far, maintenance with rituximab has been mostly
considered in relapsed and refractory FL patients. Recently
the results of the PRIMA trial were published providing
data on the use of maintenance also after first line therapy.(20)
The study included 1217 patients with previously untreated
FL needing systemic therapy. Patients received one of
three non-randomized immunochemotherapy induction
regimens used in routine practice. After induction therapy,
1019 patients achieving a complete or partial response were
randomly assigned to receive 2 years of rituximab
maintenance therapy (375 mg/m2) every 8 weeks or
observation. The primary endpoint was PFS. With a median
follow-up of 36 months, PFS was 74.9% in the rituximab
maintenance group and 57.6% in the observation group.
Overall survival did not differ significantly between groups
(Hazard ratio - HR: 0·87; 95% confidence interval - 95% CI:
0·51-1·47).(20)
In a recent meta-analysis, a search of the electronic
databases up to December 31 2010 was performed and nine
trials and 2586 FL patients were included. Refractory or
relapsed FL patients (i.e. previously treated) treated with
rituximab maintenance had improved OS and PFS compared
with those without maintenance (pooled HR of death = 0.72;
95% CI = 0.57 - 0.91), whereas previously untreated patients
had no overall survival benefit (pooled HR of death = 0.86;
95% CI = 0.60 to 1.25).(24)
Another new post-induction alternative is the use
of radioimmunotherapy (RIT) with the anti-CD20
monoclonal antibodies tositumomab, which is conjugated
to 131-iodine, or ibritumomab tiuxetan, which is linked to
90-yttrium.(25) One large randomized trial evaluated the
efficacy and safety of consolidation with 90-yttrium
(Zevalin) in patients with advanced-stage FL in first
remission. Patients who achieved a complete response,
unconfirmed complete response or partial response after
first-line induction treatment, were randomly assigned to
receive 90Y-ibritumomab tiuxetan or observation.
Consolidation with 90 Y-ibritumomab tiuxetan significantly
prolonged median PFS in all patients (36.5 versus 13.3
months in control arm).(26)
Salvage therapy
A number of salvage treatments are currently available
and may still have a chance to control relapsed, recurrent,
or resistant FL including chemoimmunotherapy regimens
not used in first-line, rituximab alone, single-agent
alkylators or a variety of nonstandard options; these are
to be considered on a patient-by-patient basis. In any case,
based on the results of randomized trials and of a recently
published meta-analysis, patients with relapsed/
progressive FL who respond to salvage immuno-
chemotherapy should receive maintenance treatment with
rituximab to reduce the risk of progression and of
death.(24,27)
The role of stem cell transplantation (SCT) remains
an important option in relapsed/progressed patients. Since
allogeneic SCT is not available for most patients and does
not guarantee better results overall,(28) autologous SCT is
most frequently used following high-dose chemotherapy
conditioning. Autologous SCT achieves long lasting
remission showing a plateau in long-term FL survival
curves.(29,30) Moreover autologous SCT seems to succeed
independent of the tumor grade(31) and is not adversely
affected by the introduction of rituximab in chemo-
immunotherapy regimens used before transplantation (PFS
at 5 years: 65% versus 33%; p-value < 0.0001).(31-33)
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Novel agents and ongoing clinical trials
One novel and yet well-established therapeutic option
for relapsed/refractory FL patients is RIT. Literature
concerning RIT has convincingly shown that single-agent,
radioconjugated monoclonal antibodies are more effective
than single-agent rituximab in terms of complete response
(30% versus 16%; p-value < 0.04) and overall response rates
(80% versus 56%; p-value < 0.002)(34) but are also more
myelosuppressive.(35)
Several new agents with different mechanisms of action
are currently being studied. Some of them are already in
advanced stage of clinical development and will soon be
made available to clinical practice. Among them the most
interesting results have been obtained with a new generation
of humanized anti CD20 monoclonal antibodies that will
hopefully have higher anti-lymphoma activity with
unchanged safe toxicity profile compared with rituximab
(Table 4).
will come from the study of tumor biology and from the use
of highly sensitive techniques such as minimal residual
disease analysis and PET and will contribute to improve the
outcomes of future patients.
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